| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | UNC1215 | GDSC1000 | pan-cancer | AAC | -0.052 | 0.1 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.051 | 0.1 |
| mRNA | KIN001-102 | GDSC1000 | pan-cancer | AAC | 0.044 | 0.1 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | -0.054 | 0.1 |
| mRNA | UNC0638 | GDSC1000 | pan-cancer | AAC | 0.044 | 0.1 |
| mRNA | LFM-A13 | GDSC1000 | pan-cancer | AAC | 0.052 | 0.1 |
| mRNA | ouabain | CTRPv2 | pan-cancer | AAC | 0.052 | 0.1 |
| mRNA | PLX4720 | CCLE | pan-cancer | AAC | -0.066 | 0.1 |
| mRNA | BRD6340 | CTRPv2 | pan-cancer | AAC | 0.052 | 0.1 |
| mRNA | 3-Cl-AHPC | CTRPv2 | pan-cancer | AAC | 0.051 | 0.1 |